If his daughter ever developed leukemia, certain metabolic diseases, or if regenerative medicine advanced enough that her own cells could treat conditions not yet identified, her biological insurance policy would be waiting.
Daniel signed up. Most parents offered this choice at the hospital sign the paperwork, hand over the credit card, and largely forget about it. The cryogenic storage fee bills annually, the cells sit in a tank somewhere in suburban Dallas, and the whole enterprise occupies roughly the same mental category as homeowner’s insurance — something hoped never to be needed but vaguely reassuring to have.
Stem cell banking has moved far beyond cord blood collection. Today’s landscape includes banking dental pulp cells, adipose-derived stem cells, bone marrow cells, and pluripotent cells generated from ordinary tissue samples. There are banks for athletes storing cells at their biological peak before injuries occur. Banks for middle-aged adults collecting their own cells before age degrades them. Banks that claim to offer future access to regenerative treatments that don’t exist yet but probably will.
And there are real questions about what all of this actually delivers, what the evidence says, and where the line between legitimate medical preparation and premium wellness theater sits.
WHAT STEM CELLS ACTUALLY ARE: BIOLOGY BEFORE BANKING
Stem cells are defined by two properties: self-renewal (the ability to divide and produce identical daughter cells) and potency (the ability to differentiate into specialized cell types). These properties exist on a spectrum.
Totipotent cells — found only in the earliest embryo immediately after fertilization — can generate every cell type in the body including placental tissue. Pluripotent cells (embryonic stem cells and induced pluripotent stem cells) can generate any cell type except placental tissue. Multipotent cells — the category that includes most of the stem cells relevant to banking — differentiate into a limited range of cell types within a specific tissue system.
Cord blood contains hematopoietic stem cells (HSCs) — multipotent cells capable of generating all blood cell types: red blood cells, platelets, the full range of immune cells. HSCs are the cells that can reconstitute the entire blood and immune system after it’s been destroyed by chemotherapy, which is the basis of bone marrow (and cord blood) transplantation for leukemia and other blood cancers.
Mesenchymal stem cells (MSCs) are multipotent cells found in bone marrow, adipose tissue, dental pulp, and many other tissues. They differentiate into bone, cartilage, muscle, and fat cells, making them the primary candidate for skeletal tissue repair. They also carry important immunomodulatory properties — they can suppress inappropriate immune responses — relevant for autoimmune diseases and inflammatory conditions.
Neural stem cells reside in specific niches in the brain and spinal cord and generate neurons and glial cells, though with limited regenerative capacity compared to other stem cell types. Cardiac progenitor cells have been identified in heart tissue and studied as a potential therapy for heart failure, though the clinical results have been mixed.
Stem cell biology changes with age in ways that bear directly on banking strategy. HSCs become fewer, less functional, and more biased toward myeloid cell production (at the expense of lymphoid cells) with age. MSCs become less proliferative, less differentiation-capable, and more inflammatory with age. Neural stem cell niches shrink and slow down.
This age-related decline in stem cell function is one of the primary mechanisms behind impaired tissue repair in aging — and it’s the fundamental argument for banking cells while young and functional rather than harvesting them decades later, after age has already done its work.
CORD BLOOD BANKING: THE ESTABLISHED APPLICATION WITH REAL CLINICAL USE
Cord blood banking is the most established form of stem cell banking with the deepest evidence base. The hematopoietic stem cells in cord blood have been used in over 40,000 transplants worldwide for more than 80 diseases, primarily blood cancers and hemoglobinopathies.
The clinical case for cord blood use is strongest in pediatric hematological malignancies. For a child diagnosed with leukemia who needs a bone marrow transplant, their own cord blood offers the ideal autologous transplant: a perfect HLA match (no rejection risk), cells free of the malignant clones present in the patient’s current marrow (assuming the cancer isn’t of cord-blood origin), and immediate availability with no donor search delay.
However, the probability that any given child will actually need their own cord blood is the central argument against private banking. The American Academy of Pediatrics (AAP) has consistently stated that the probability of a child using their own banked cord blood falls between 1 in 2,700 and 1 in 200,000 over a lifetime — depending on which conditions are counted.
For most families, the $2,000-$3,500 upfront cost plus $100-$200 in annual fees is a significant investment against a very small probability of use.
The AAP’s recommendation: private banking is medically justified for immediate family members with a known condition treatable by HSC transplant — a sibling with leukemia, a parent with a hereditary blood disorder. For families without that specific need, public cord blood donation, which costs nothing and makes the cells available to patients who need them, is the more socially optimal choice.
Public banks cost nothing for families, are covered by hospital systems, and contribute to a resource serving patients who lack compatible bone marrow donors.
The emerging use cases for cord blood — potential applications in regenerative medicine beyond blood cancers, potential future treatments using MSCs from cord tissue (Wharton’s jelly), potential iPSC generation from banked cells — are plausible reasons private banking might prove retrospectively valuable. But they remain speculative, and the AAP’s conservative position reflects the appropriate evidence standard for medical recommendations.
DENTAL PULP STEM CELL BANKING: THE SURPRISING OPTION MOST PEOPLE MISS
Dental pulp stem cells (DPSCs) may be the most overlooked opportunity in stem cell banking. When children lose baby teeth — or when anyone has wisdom teeth extracted — the dental pulp inside those teeth contains mesenchymal stem cells that can be collected, processed, and banked for future use.
DPSCs have several traits that make them attractive for regenerative medicine. Easily accessible — tooth extraction is a routine procedure producing naturally available tissue. Highly proliferative compared to bone marrow MSCs. Able to differentiate into osteoblasts, chondrocytes, adipocytes, neurons, and cardiac muscle cells in laboratory conditions. Carry immunomodulatory properties that make them candidates for treating autoimmune and inflammatory conditions. And critically, they’re banked at a biological age — the donor’s age at extraction — that won’t increase.
Companies like Store-A-Tooth (now BioEden) and StemSave offer processing and long-term cryogenic storage of DPSCs from extracted teeth. The procedure: the tooth must reach the processing lab within 48 hours of extraction, live cells get extracted from the pulp, viability-tested, and preserved at ultra-low temperatures. Typical costs run $600-$1,800 for processing plus $100-$180 in annual storage fees.
The evidence for clinical DPSC applications is mostly preclinical — animal models and in vitro studies showing impressive regenerative capabilities — with a small but growing number of early-phase human trials. The most advanced research areas: neurological applications (DPSC-derived neural cells studied for Parkinson’s disease and spinal cord injury), bone and cartilage repair, and cardiac repair. None of it is currently an FDA-approved therapeutic standard of care.
The cost-benefit analysis for DPSC banking is better than for most stem cell banking: the cells come from tissue that would otherwise be discarded, the collection is non-invasive beyond the tooth extraction that was already happening, and storage costs run modest compared to cord blood banking. If regenerative medicine develops even modestly in the direction the field is heading, having young, healthy, autologous mesenchymal stem cells available in thirty years seems likely to carry some value.
The question is whether that value exceeds the certainty of the ongoing storage cost.
ADULT STEM CELL BANKING: ADIPOSE AND BONE MARROW SOURCES
Adipose tissue contains a relatively high concentration of mesenchymal stem cells, technically called ADRCs (adipose-derived regenerative cells) or, depending on processing, ADSCs (adipose-derived stem cells). They can be harvested through a mini-liposuction procedure — relatively low-invasiveness, usually under local anesthesia — then either used immediately or processed for cryogenic banking. Companies like Forever Labs, RenewMe, and various direct clinical providers offer this service.
The advantage of adipose MSCs is abundance: fat tissue yields far more MSCs per gram than bone marrow, making collection simpler and less painful. The disadvantage is somewhat lower potency for certain differentiation pathways, particularly osteogenic, compared to bone marrow MSCs. For applications requiring bone or blood cell generation, bone marrow remains the superior source.
Bone marrow MSC banking — offered by companies like Forever Labs for adult banking — involves a bone marrow aspiration, typically from the posterior iliac crest, extracting both HSCs and MSCs. More invasive than fat aspiration, requiring local anesthesia and producing more discomfort, but it yields both cell types and preserves access to HSCs that can reconstitute the immune system after bone marrow suppression.
The age argument for adult banking is simple: MSC function declines with age, and cells banked at 35 are biologically superior to cells that would be harvested at 65. Banking at a healthy biological prime preserves young, functional cells before epigenetic aging, oxidative damage, and reduced self-renewal capacity diminish their utility.
This is mechanistically sound — studies consistently show MSCs from younger donors outperform those from older donors in proliferation, differentiation capacity, paracrine signaling, and immunomodulatory function.
INDUCED PLURIPOTENT STEM CELLS: THE TECHNOLOGY THAT CHANGES EVERYTHING
The implications for banking run deep. Bank any cells — skin cells, blood cells, fat cells — and a laboratory can theoretically generate iPSCs from them down the line, and from those iPSCs, generate essentially any cell type a future treatment needs. Cardiac cells for a damaged heart. Neurons for a degenerating brain. Beta cells for a failing pancreas. Retinal cells for macular degeneration. Any cell type from any tissue, derived from a person’s own young cells.
Several companies now bank cells specifically for potential iPSC generation, including Lifespan Cell Bank and various early-stage ventures. The current limitation is mostly technological: iPSC generation and subsequent differentiation into specific cell types is complex, expensive, and still requires significant quality control to ensure the resulting cells are safe (particularly regarding tumorigenic potential from incomplete reprogramming) and functional. These limitations are actively being addressed, and the pace of progress is fast.
The strategic implication: banking ordinary somatic cells today — blood, skin, even stored PBMC (peripheral blood mononuclear cells) from routine blood draws — may be a cost-effective way to preserve the option for iPSC-based therapies down the road. If iPSC technology keeps developing as projected, the cells banked today become far more versatile than their current classification suggests.
The MSCs banked at 40 might be used as MSCs if needed, but if not, they can also be reprogrammed to iPSCs and used to generate neurons, cardiac cells, or cell types not yet identified as therapeutic targets.
CURRENT CLINICAL REALITY: WHAT IS ACTUALLY BEING TREATED WITH BANKED STEM CELLS?
The gap between the marketing claims of stem cell banking companies and the actual clinical applications currently available is wide enough to need explicit mapping.
What’s definitively established and in clinical use: Hematopoietic stem cell transplantation (HSCT) using cord blood, bone marrow, or peripheral blood stem cells is a standard of care for over 80 hematological conditions. Acute myeloid and lymphoid leukemias, chronic leukemias, lymphomas, multiple myeloma, aplastic anemia, sickle cell disease, thalassemia, severe combined immunodeficiency (SCID), and several metabolic storage diseases are treatable with HSCT. Autologous HSCT (using a patient’s own cells) is standard for multiple myeloma and certain lymphomas.
Allogeneic HSCT (using donor cells) is necessary for conditions where the patient’s own marrow is the disease source.
What’s in clinical trials with promising data: MSC therapy for graft-versus-host disease (already approved in Canada and Europe, in late-stage trials in the US), MSC therapy for Crohn’s disease (approved in Japan), MSC therapy for knee osteoarthritis (multiple phase 2-3 trials showing reduced pain and improved function), and MSC therapy for heart failure (small but consistent trials showing modest improvements in ejection fraction and exercise capacity).
What’s in early-phase trials with preliminary data: Neural stem cell therapy for Parkinson’s disease, DPSC therapy for neurological applications, iPSC-derived cell therapies for retinal diseases (Riken Institute in Japan reported the first human iPSC retinal transplant in 2014 with safety established, efficacy trials ongoing), and CAR-T cell therapies for cancer (using a patient’s own T cells, genetically modified — the most clinically advanced personal cell banking application currently in use).
What’s being marketed without adequate clinical support: Many direct-to-consumer stem cell “treatments” offered in clinics in Mexico, Central America, and other jurisdictions outside strict regulatory oversight claim to treat conditions from autism to ALS to anti-aging with stem cell injections. The FDA has consistently warned against these unproven treatments, and adverse events including infections, tumor growth, and even death have been documented.
None of this is what reputable banking companies offer. It’s a separate, problematic industry that has attached itself to the scientific legitimacy of real stem cell research.
THE REGENERATIVE MEDICINE TIMELINE: WHAT’S ACTUALLY COMING AND WHEN
Banking decisions should be informed by realistic expectations about when banked cells might become therapeutically useful beyond current applications. Projections in regenerative medicine have historically run overoptimistic in the short term, but the field is accelerating in ways that make medium-term projections more credible.
Five to ten years: MSC-based therapies for osteoarthritis, inflammatory bowel disease, and GVHD will likely receive broader regulatory approval. CAR-T approaches will expand to solid tumors (current clinical trials show early promise). iPSC-derived retinal cells will likely receive approval for specific retinal conditions.
Ten to twenty years: iPSC-derived dopaminergic neurons for Parkinson’s disease are one of the most advanced pipeline candidates, with multiple Phase 1/2 trials underway. iPSC-derived cardiomyocytes for heart failure are in earlier trials but the biology is compelling. Organoid-based approaches — creating organ-on-chip tissue from patient cells — will enable personalized drug testing and eventually tissue transplantation for specific organs.
Twenty to forty years: more speculative, but potentially including whole-organ bioengineering from patient cells (kidney, liver, lung transplants without donor dependency), neural regeneration for neurodegenerative diseases (the hardest target given neuronal complexity), and epigenetic reprogramming combined with cell therapy to actually reverse cellular aging rather than just replace damaged tissue.
This is the time horizon where the iPSC banking younger adults are doing today might prove most valuable — not for current applications but for applications that will exist when those people are in their seventies and eighties.
HOW TO EVALUATE A STEM CELL BANKING COMPANY
Accreditation and regulatory status: legitimate cord blood banks are accredited by AABB (formerly the American Association of Blood Banks), FACT (Foundation for the Accreditation of Cellular Therapy), or equivalent international bodies. These accreditations require standardized processing, quality testing, and storage protocols. Companies without them may not be processing or storing cells to standards that maintain clinical utility.
Cell viability testing: any reputable bank should test cell viability at collection, after processing, and report those results back. Ask specifically: what percentage of cells are viable after processing? What viability testing happens on samples before cryopreservation? A good answer is 85%+ viability confirmed by standardized assays. Vague answers about “high-quality processing” with no specific numbers are a warning sign.
Storage security and business continuity: the bank needs a plan for what happens to stored cells if the company goes out of business, loses its facility, or gets sold. Look for long operating histories, clear contractual terms about cell ownership and transfer rights, and redundant storage facilities. Ask specifically: what happens to my cells if your company ceases operations?
Therapeutic specificity: be skeptical of companies promising banked cells will treat a specific wide range of conditions. Reputable banks describe current established uses and acknowledge that future applications are promising but uncertain. Companies listing twenty conditions their cells will “likely” treat are making claims beyond what evidence supports.
What People Ask About Stem Cells Actually: STEM CELL BANKING
Is private cord blood banking worth it if there’s no family history of blood cancer?
For a typical family without known hereditary hematological conditions or an affected family member, the AAP’s position is that the probability of use is low enough that public donation is the medically preferable choice.
The probability calculation shifts if the thinking extends beyond current HSC applications: if MSCs from cord tissue (Wharton’s jelly) prove valuable for orthopedic and inflammatory applications in the next twenty years — a reasonable expectation given the clinical trial pipeline — and if the bank collects and stores cord tissue alongside cord blood, the cost-benefit tilts somewhat.
The decision ultimately comes down to how much weight gets assigned to uncertain future applications versus the certain cost of storage.
At what age is it too late to bank your own adult stem cells?
There’s no hard cutoff, but the functional decline of MSCs with age is real and accelerates significantly after sixty. Banking in the forties is substantially better than banking in the sixties from a cell quality standpoint.
That said, even cells banked in the late fifties or sixties are biologically superior to cells that would be harvested at that same age for immediate use later — the banked cells are frozen at their current age and won’t age further in storage.
The argument for banking is strongest in the thirties and forties, when cells are biologically youngest, but it remains present at older ages if treatments requiring autologous cells become available when a person is in their seventies and eighties.
What’s the difference between what stem cell banking companies promise and what’s actually proven?
The gap is large but context-dependent. For cord blood HSC applications, the promise is well-substantiated — proven medical technology. For adult MSC banking aimed at future orthopedic and inflammatory applications, the promise rests on genuinely promising but still largely early-to-mid-stage clinical evidence.
For the broader “protect against any future regenerative medicine need” marketing angle, the promise is speculative but not unreasonable given the pace of the field — an option value argument rather than a demonstrated clinical benefit. For anyone marketing autologous cells as a current treatment for neurological diseases, cancer types not established in clinical trials, or anti-aging effects, the evidence does not currently support those claims.
Should athletes bank their stem cells at peak performance?
The concept is being marketed specifically by companies targeting athletes, arguing that banking MSCs while young and in peak condition preserves the optimal repair cells for future orthopedic applications — knee, hip, shoulder repairs and replacements — that many athletes eventually need. Mechanistically sound: MSCs collected at 28 and stored cryogenically will be biologically younger and more functional than cells collected at 52 when the knee arthritis requiring treatment actually shows up.
Whether orthopedic MSC therapies will be sufficiently advanced by the time those cells are needed is the primary uncertainty. Given the pace of knee and hip MSC trial development, this seems like a reasonable gamble for athletes, particularly those whose careers involve heavy joint loading.
Can banked cells survive cryogenic storage indefinitely?
Theoretically, cells stored in liquid nitrogen at -196°C experience negligible biological time — all metabolic processes suspended. Cord blood samples stored for over 20 years have been successfully used in transplants with maintained viability. The longest stored samples, dating back to the early cord blood banking programs of the 1990s, show good viability at 25+ years.
There’s no theoretical upper limit to cryogenic storage duration; the challenge is practical infrastructure — maintaining liquid nitrogen levels, preventing equipment failure, ensuring institutional continuity — rather than the biology of the cells themselves. Banks that have operated for 20+ years and maintain accreditation offer the most confidence that long-term storage quality is holding up.
“The cells you preserve today are a conversation with your future self about what options you want to have. The question isn’t whether those options will exist. The question is whether you’ll have access to them when they do.” — Greg Fahy, cryobiologist
Daniel’s daughter is eight now. The cells sit in liquid nitrogen in suburban Dallas, aging approximately not at all, while regenerative medicine advances at a pace that makes the field of cellular therapy in 2035 genuinely hard to predict. They might never be needed. They might save her life. They might enable a treatment for a condition that isn’t even recognized as treatable today.
That’s the honest status of stem cell banking: an insurance policy against biological uncertainties, priced differently depending on what’s being insured against, with some applications already proven and others still speculative. The appropriate framework is option value — not buying a treatment, buying the right to access one if it becomes available. Option value is real, even when the exact payoff is uncertain.
The question worth asking is whether the option’s price tag — annual storage fees, collection procedure costs — is proportionate to a fair estimate of that value given a person’s specific health profile, family history, and time horizon.
Sometimes the answer is yes. Sometimes it isn’t. But making the decision based on a clear-eyed read of what stem cells actually are, what the clinical pipeline actually contains, and what the biological clock of a person’s own cells actually means — rather than brochure marketing — is at minimum worth the thirty minutes it takes to read past the optimistic headlines.
REGULATORY LANDSCAPE: WHAT YOU CAN AND CANNOT DO WITH BANKED CELLS
Understanding what’s legally permitted with banked cells matters as much as understanding the biology. The regulatory framework governing cellular therapies is complex, jurisdiction-dependent, and evolving fast as the technology outpaces existing frameworks.
In the United States, the FDA regulates human cellular therapy products under 21 CFR Part 1271 (Human Cells, Tissues, and Cellular and Tissue-Based Products, or HCT/Ps). The FDA distinguishes between “minimally manipulated” cell products (processed without significantly altering their biological characteristics) and “more than minimally manipulated” products (extensively processed or combined with non-cellular components). Minimally manipulated, same-person (autologous) cells used for homologous purposes — the same function they perform in the body — receive a lower regulatory burden than other categories.
This regulatory distinction matters practically. Banking cord blood for potential autologous HSC transplantation falls in the lower regulatory burden category — the cells are minimally processed and used for the same hematopoietic function they perform in the body.
But cells that are extensively cultured, expanded, or differentiated into new cell types — which is what most of the more speculative future applications would require — fall under a stricter FDA pathway requiring Investigational New Drug (IND) applications and clinical trial frameworks. Banked cells can’t simply be used however someone chooses — the treatment application has to sit within the regulatory framework appropriate to the level of cell manipulation involved.
This is a critical distinction stem cell banking companies sometimes obscure in their marketing materials. The cells banked are legally the owner’s. But accessing them for a specific therapeutic application requires that application to either be FDA-approved or conducted under appropriate clinical trial oversight. Banking in anticipation of future approved therapies is reasonable — those therapies will exist within a regulatory framework that allows the cells to be used.
Banking in hope of accessing unapproved experimental treatments through regulatory arbitrage — offshore clinics, for example — exposes a person to the significant risks of unproven cellular interventions with no clinical oversight.
The international regulatory landscape is more heterogeneous. Japan’s Act on the Safety of Regenerative Medicine (2014) and subsequent regulatory reforms created one of the most permissive frameworks for regenerative medicine in any developed economy, allowing conditional approval of cellular therapies with early safety data pending full efficacy demonstration. Which is why several iPSC-based therapies had their first human applications in Japan — the regulatory pathway there allows earlier clinical use of emerging technologies.
European regulations (under the Advanced Therapy Medicinal Products framework) are stricter than Japan’s but structured to allow faster development timelines than the US for some cellular therapy categories.
THE LONGEVITY MEDICINE INTERSECTION: BANKING FOR SYSTEMIC AGE REVERSAL
The stem cell banking conversation increasingly intersects with the longevity medicine and age-reversal movement in ways worth examining carefully. Several companies market cell banking specifically in the context of future epigenetic reprogramming therapies — the idea that partial Yamanaka factor reprogramming (as demonstrated in Sinclair’s lab for retinal cells) will eventually be applied systemically, and that having young cells already banked will be necessary to take advantage of it.
The logic runs like this: epigenetic reprogramming, if it works systemically in humans, will restore youthful gene expression to aging cells. But reprogramming a current 60-year-old’s cells restores the 60-year-old epigenetic baseline — the information is theoretically still there, but the cells have accumulated decades of oxidative damage, mitochondrial mutations, and telomere shortening that reprogramming alone may not reverse. Banking cells from 35-year-old biology preserves cells that, when reprogrammed, would potentially restore a much younger functional state.
This is speculative — epigenetic reprogramming in living humans is years to decades from clinical availability, and the interaction between banked young cells and future reprogramming therapies is entirely theoretical. But the speculation is scientifically grounded in real biology, and the companies making this argument aren’t selling pure fantasy. They’re making a Bayesian bet that the option value of young-biology cells will matter in a world where cellular rejuvenation becomes medically feasible.
The honest assessment: this is one of the more intellectually defensible arguments for adult stem cell banking, even with a long time horizon and an uncertain probability of payoff. For someone in their thirties who believes — as a growing number of mainstream scientists do — that partial reprogramming will be clinically available within twenty to thirty years, banking cells now preserves the biologically “youngest” option for accessing that technology.
The cost is real, the probability is uncertain, and the option value is contingent on the broader longevity medicine field delivering on ambitious promises. Whether that’s a reasonable bet depends on how much weight gets assigned to the transformative possibility versus the certain ongoing cost.
THE ETHICAL DIMENSIONS: WHO BENEFITS AND WHO DOESN’T
Stem cell banking raises ethical questions sitting at the intersection of medical technology, economic access, and societal resource allocation — questions worth confronting rather than skipping past in any complete treatment of the subject.
Access inequality is immediate and obvious. Private cord blood banking costs $2,000-$3,500 upfront plus $100-200 annually — accessible to middle and upper-middle-class families but meaningfully burdensome for lower-income families. Adult stem cell banking costs $1,500-$4,000 for the collection procedure plus ongoing storage. iPSC banking and the associated future therapies will likely stay expensive for decades after their first clinical applications.
The result is a tiered regenerative medicine future in which the wealthiest individuals have banked cells from their biological prime and access to the most advanced cellular therapies, while less affluent individuals rely on donor cells — with HLA matching requirements and availability limitations — or miss the window for autologous options entirely.
Public cord blood banking represents the more equitable alternative for the perinatal window. Donated cord blood, pooled in public banks, is available to any patient who needs HSC transplantation and finds a compatible unit — regardless of whether their own cord blood was saved. Public banks have produced over 40,000 transplants worldwide and saved tens of thousands of lives, predominantly in patients who couldn’t find matched bone marrow donors.
The case for preferring public donation over private banking, for families without specific medical needs, is both epidemiological (the probability of individual use is low) and ethical (the societal value of donated cord blood runs very high).
The more profound ethical question is whether the emerging regenerative medicine infrastructure will follow the pattern of other medical advances — eventually becoming accessible across income levels as costs fall — or stay a premium service that widens health outcome disparities. CAR-T therapy costs $375,000-$450,000 per patient currently. Gene therapies are priced in the millions.
If cellular age-reversal therapies follow that pricing trajectory, the longevity medicine advances of the coming decades may extend healthy lifespan primarily for those who can afford them — creating a literal biological inequality between rich and poor that dwarfs current health disparities.
None of this is an argument against pursuing or discussing stem cell banking. It’s an argument for holding these conversations in full view of who benefits and who doesn’t, for supporting the public banking infrastructure that makes cellular medicine more accessible, and for expecting the researchers and companies developing these technologies to treat access as a design problem — not an afterthought that market forces will eventually solve.
The Practical Framework: Applying Stem Cells Actually Biology In Real Life
References